Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. FBRX
FBRX logo

FBRX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Forte Biosciences Inc (FBRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
26.320
1 Day change
3.22%
52 Week Range
35.620
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Forte Biosciences Inc (FBRX) is not a strong buy at the moment for a beginner investor with a long-term focus. The lack of positive catalysts, weak financial performance, and absence of significant trading signals suggest holding off on this stock for now.

Technical Analysis

The stock is trading at $27.23, with a regular market change of +2.39%. The MACD histogram is below 0 and negatively contracting, indicating weak momentum. RSI is neutral at 58.282, and moving averages are converging, showing no clear trend. The stock is near its pivot level of 25.821, with resistance at 28.728 and support at 22.914.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
6

Positive Catalysts

  • NULL identified. There is no recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • and net income (-$17.68M) despite YoY improvement. No recent congress trading data or influential figure activity. High implied volatility (153.

  • suggests uncertainty.

Financial Performance

In Q3 2025, revenue remained at $0 with no growth. Net income improved by 110.70% YoY but is still negative at -$17.68M. EPS dropped significantly by -78.19% YoY, reflecting poor profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for review.

Wall Street analysts forecast FBRX stock price to rise
2 Analyst Rating
Wall Street analysts forecast FBRX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 25.500
sliders
Low
65
Averages
65
High
65
Current: 25.500
sliders
Low
65
Averages
65
High
65
Evercore ISI
Outperform
initiated
$65
AI Analysis
2025-11-25
Reason
Evercore ISI
Price Target
$65
AI Analysis
2025-11-25
initiated
Outperform
Reason
Evercore ISI initiated coverage of Forte Biosciences with an Outperform rating and $65 price target. There has been a notable re-rating in development-stage microcap companies, especially those with important proof of concept data in 2025 and 2026, notes the analyst. While arguing that Forte "falls squarely in this bucket," the firm notes shares have been slow to get the same bid until the last two weeks, adding that it thinks the setup is "super attractive into a catalyst-rich 2026."
Guggenheim
NULL -> Buy
initiated
$75
2025-08-18
Reason
Guggenheim
Price Target
$75
2025-08-18
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of Forte Biosciences with a Buy rating and $75 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for FBRX
Unlock Now

People Also Watch